🔗 Share this article

A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Drug Gaining Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged fat-burning effects. Followers are encouraged to contact these profiles privately for source information, while also receiving promotional offers.

Active Trade on Messaging Platforms

Additionally, a robust trade exists on Telegram, where groups with thousands of members share comparison images, administration instructions and assertions of rapid British shipping. Sellers market the substance there before redirecting buyers to other platforms for purchases.

Understanding Retatrutide

Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist patients reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being hailed online as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, doctors and chemists have warned that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals injecting substances of uncertain source.

Several experts stated the demand for the experimental drug could be linked to the increasing cost of licensed slimming products such as Mounjaro.

Regulatory Position and Implementation

Selling retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Some content creators attempt to sidestep the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but promotion and supply can still breach pharmaceutical, advertising, and customer regulations, potentially leading to fines, legal action or prison.

Platform Reaction and Material Removal

According to the social media company, the platform has removed violative material and prohibited associated hashtags and search suggestions. The organization said it was dedicated to keeping the service secure and allocating resources in strengthening compliance measures.

Digital Marketplace Activities

Research also found communities with up to nine thousand participants marketing retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, filled with photos of slimming results, glowing reviews and step-by-step instructions for mixing or administering at home.

Within minutes of entering one community, a seller posted contact information, where most transactions occur. The seller provided an guidebook and promised delivery within two days. When asked whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. Not one asked about weight, medical conditions or past usage.

Product Information and Costs

Within these communities, posts show black plastic parcels with Royal Mail labels, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at residence with purified liquid, or pre-filled pens usually sold at £160 for 20mg. When questioned how much time a pen should be used, vendors give conflicting responses ranging from a several days to “depends on your body”.

Platform Oversight and Safety Actions

A representative for the messaging service said it actively monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are injecting substances they can’t verify. Even if the science behind retatrutide is valid, these online versions may not include what they claim,” stated Jason Murphy, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor connected the increase in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With prices increasing, individuals are using social media. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was clean,” she explained.

Her team has already encountered patients injured by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These substances could be impure or improperly measured.”

Producer Statement

A representative from Eli Lilly said the substance was in phase 3 research studies and had not been evaluated or approved by any government authority anywhere in the world. “Therefore at this point no one can market [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a Lilly investigational product not yet approved … may subject patients to potentially significant health risks”.